Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times

This study has been completed.
Sponsor:
Information provided by:
Renovo
ClinicalTrials.gov Identifier:
NCT00984516
First received: September 24, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted
  Purpose

The purpose of this study was to investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only or three times in male and female subjects and to collect further safety and tolerability data for intradermal Juvidex in male and female subjects.


Condition Intervention Phase
Cicatrix
Wound-healing
Drug: Juvidex
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.

Resource links provided by NLM:


Further study details as provided by Renovo:

Primary Outcome Measures:
  • To investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only and three times in male and female subjects. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To collect further safety and tolerability data for various doses and dosing frequencies of intradermal Juvidex in male and female subjects. [ Time Frame: 1 hour to 24 months ] [ Designated as safety issue: Yes ]
  • To assess systemic exposure to Juvidex, following various doses and dosing frequencies of intradermal Juvidex, before and after making minor skin incisions in male and female subjects. [ Time Frame: 1 hour to 12 months ] [ Designated as safety issue: Yes ]

Enrollment: 102
Study Start Date: August 2004
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intradermal Juvidex Drug: Juvidex
Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Drug: Juvidex
Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Drug: Juvidex
Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Drug: Juvidex
Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Drug: Juvidex
Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Drug: Juvidex
Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Other Names:
  • Mannose-6-phosphate
  • M6P
  • RN1004
Placebo Comparator: Placebo (vehicle) Drug: Placebo
Intradermal Placebo, 100μl administered once prior to wounding
Drug: Placebo
Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)

Detailed Description:

Subjects were randomised into three dose groups of equal size. The three dose groups were 100mM (2.82mg/100μl), 200mM (5.64mg/100μl) and 400mM (11.28mg/100μl). Before wounding, three prospective wound sites 1cm long were marked on the upper, inner aspect of each arm (anterior, posterior and distal) to give three pairs of wounds. Wounds were assigned as Pair 1 (left distal and right distal), Pair 2 (left anterior and left posterior) and Pair 3 (right anterior and right posterior).

Sites were anaesthetised using 1% plain lignocaine, then prior to wounding one site from each pair, randomly assigned, received an intradermal injection of Juvidex (100μl) and the opposite site from each pair received an intradermal injection of Placebo (100μl).

Within dose groups, subjects were randomised into two subgroups of similar size. Subgroup A received one dose in wound pairs 1 and 2; and three doses in wound pair 3. Subgroup B received three doses in wound pairs 1 and 2; and one dose in wound pair 3. Incision sites randomised to receive three injections of study medication were re-dosed with 100μl per wound margin (200μl per site) 3 hours after receiving the first dose and dosed again in the same way on Day 5.

Subjects attended a follow-up visit on Day 14. Scars were assessed monthly from Month 1 to Month 12. At Month 12, the Investigator excised the distal scars from each subject for histological examination. Posttrial follow-up visits are scheduled for Months 18 and 24.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects aged 18-45 years who gave written informed consent
  • Weight between 50-150kg with a BMI within the permitted range for their height using Quetelet's index: weight (kg)/height (m)2. The permitted range was 15-55kg/m2
  • Female subjects of childbearing potential who were deemed by the Investigator to be using adequate contraception at the time of screening and who agreed to continue using this form of contraception for the duration of the trial
  • In the opinion of the Investigator, and on the basis of the investigations carried out within 12 weeks prior to the first study drug dose (determined by results of electrocardiogram [ECG], physical examination, medical history, haematology and biochemistry blood results) the subject was in adequate health to undertake the trial

Exclusion Criteria:

  • Subjects who on direct questioning and physical examination had a history or evidence of hypertrophic or keloid scarring or had tattoos in the area to be incised
  • Afro-Caribbean subjects because of their increased susceptibility to hypertrophic and keloid scarring
  • Subjects who had surgery in the area to be incised within one year of the first dosing day
  • Subjects with a history of a bleeding disorder
  • Subjects who, on direct questioning and physical examination, had evidence of any past or present clinically significant disease, particularly coagulation disorders, diabetes, immuno-mediated conditions and skin diseases and allergies, such as clinically significant eczema
  • Subjects with a skin disorder that was chronic or currently active and which the Investigator considered would adversely affect the healing of the acute wounds or would involve the areas to be examined in this trial
  • Subjects with any clinically significant medical condition that would impair wound healing including; significant rheumatoid arthritis, chronic renal impairment significant for their age, significant hepatic impairment (LFTs >3 times upper limit of normal), congestive heart failure, current active malignancy or history of malignancy in the last 5 years, immunosuppression or chemotherapy within the last 12 months, a history of radiotherapy and diabetes mellitus
  • Subjects with a history of clinically significant drug hypersensitivity to lignocaine or an allergy to surgical dressings to be used in this trial
  • Subjects who were taking or had taken any investigational product or participated in a clinical trial within the three months prior to first study drug dose for this trial
  • Subjects who were taking regular, continuous, oral corticosteroid therapy
  • Subjects who, in the opinion of the Investigator, were not likely to complete the trial for whatever reason
  • Subjects who were, or who became, pregnant or were lactating, up to and including the time of the first dose of study drug
  • Subjects undergoing/awaiting investigations or change in management for an existing medical disorder
  • Subjects who had evidence of drug abuse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00984516

Locations
United Kingdom
Renovo
Manchester, United Kingdom, M13 9XX
Sponsors and Collaborators
Renovo
Investigators
Principal Investigator: James Bush Renovo
  More Information

No publications provided

Responsible Party: John Hutchison, Medical Director, Renovo
ClinicalTrials.gov Identifier: NCT00984516     History of Changes
Other Study ID Numbers: RN1004-319-1002
Study First Received: September 24, 2009
Last Updated: September 24, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Renovo:
Cicatrix
Scar
Wound-healing
Juvidex
Mannose-6-phosphate
M6P
RN1004

Additional relevant MeSH terms:
Cicatrix
Fibrosis
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014